The transfer of maternal γ-globulin (IgG) provides the neonate with humoral immunity during early life. In humans, maternal IgG is transported across the placenta during the third trimester of pregnancy. The expression of the MHC class I-related receptor, FcRn, in the human placenta suggests that this Fc receptor might be involved in the delivery of maternal IgG, but direct evidence to support this is lacking. In the current study an ex vivo placental model has been used to analyze the maternofetal transfer of a recombinant, humanized (IgG1) antibody in which His435 has been mutated to alanine (H435A). In vitro binding studies using surface plasmon resonance indicate that the mutation ablates binding of the antibody to recombinant mouse and human FcRn. Relative to the wild-type antibody, the H435A mutant is deficient in transfer across the placenta. Significantly, the mutation does not affect binding to FcγRIII, an FcR that has been suggested in earlier studies to mediate the transfer of maternal IgG. The analyses demonstrate that binding of an IgG to FcRn is a prerequisite for transport across the perfused placenta. FcRn therefore plays a central role in the maternofetal delivery of IgG and this has implications for the use of protein engineering to improve the properties of therapeutic antibodies.
Introduction
Transfer of γ-globulin (IgG) from mother to young provides Analyses in β 2 -microglobulin-deficient mice that do not express functional FcRn indicate that in addition to being the neonate with essential humoral immunity during the first few weeks (rodents) or months (humans) of life. In rodents, involved in the delivery of maternal IgG to offspring, this Fc receptor is responsible for maintaining constant serum IgG the MHC class I-related receptor, FcRn (Fc receptor, n ϭ neonatal), is known to mediate the transport of maternal IgG levels (12) (13) (14) . This is consistent with the close correlation between binding affinity of an IgG or Fc for FcRn and its across the neonatal brush border (1-4) or the fetal yolk sac during gestation (4) (5) (6) . More recent analyses have identified serum half-life and maternofetal transfer in mice (6, (15) (16) (17) , and suggests that FcRn can carry out multiple roles depending the expression of a human ortholog of FcRn in the placental syncytiotrophoblast (7) (8) (9) (10) , suggesting that this FcR may also on its location in the body (reviewed in 18). FcRn appears to be able to perform these apparently diverse functions by play a role in the maternofetal transfer of IgG in humans. However, it is still an unanswered question as to which IgGbinding and transporting IgG within and across cells in either a recycling or transcytotic route (18) . FcRn is therefore binding proteins in the placenta are involved in the transfer of maternal IgG (reviewed in 11). A corollary of this question believed to act as a 'protective' receptor and IgG that enters FcRn-expressing cells in the absence of binding to this FcR is what are the molecular properties of an IgG that endow it with the ability to be transferred?
is destined for degradation. To date, the molecular details of FcRn trafficking are poorly understood, although conserved [a generous gift of Dr J. Foote (26) ] by electroporation. Transfectants were selected as described (26) and cloned dileucine-and tryptophan-based motifs in the cytoplasmic tail have been shown to regulate FcRn internalization (19, 20) .
by limiting dilution. Supernatants of clones were analyzed by ELISA with HEL (Sigma, St Louis, MO)-coated plates using Despite the limited knowledge of FcRn trafficking, much is known about the interaction site of FcRn on IgG. Recombinant an anti-human IgG (Fc fragment)-horseradish peroxidase conjugate (ICN, Aurora, OH) for detection. Clones secreting Fc fragments with mutations of isoleucine 253 (Ile253), histidine 310 (His310) and histidine 435 (His435) have lower the highest levels of antibody were used for expression. Recombinant antibodies were purified from the culture superbinding affinity for FcRn and reduced activity in FcRn-mediated functions in mice (15, 17, 21) . The involvement of these natants of expanded clones using HEL-Sepharose and the methodology described by Foote and Winter (26) . Dr J. Foote histidines in the IgG:FcRn interaction most likely accounts for the pH dependence of complex formation (21, 22) , with binding generously provided transfectants for the expression of the wild-type humanized anti-HEL D1.3 antibody (26) . Purified at pH 6.0 and release at pH 7.4 (1). The residues involved in binding to FcRn are located at the C H 2-C H 3 domain interface proteins were analyzed by SDS-PAGE. (15, 17, 23, 24) and are distinct to those that mediate FcγR
Recombinant FcRn binding (reviewed in 25).
In the current study we have used an ex vivo placental The gene encoding human FcRn α chain (7) was isolated using RT-PCR and RNA from HT-29 cells (ATCC, Rockville, transfer model to investigate a role for FcRn in mediating IgG transfer across the human placenta. The transfer of a MD). The gene was tailored with 5Ј EcoRI-BclI sites and a 3Ј SalI site using the following primers: hFcRnback 5Ј-ATCA recombinant, humanized (IgG1) antibody has been compared with that of a mutated variant (His435 to alanine; H435A) that GAA TTC TGA TCA ATG GGG GTC CCG CGG CCT CAG CCC-3Ј and hFcRnfor 5Ј-ATCA GTC GAC CAG CTC CAC does not bind to FcRn. The data indicate that binding to FcRn is essential for an IgG to be transferred across the human CCT GAG GGG-3Ј. A DNA duplex encoding a polyhistidine tag was ligated into the SalI site. The gene for the α chain placenta, directly implicating this FcR in the maternofetal transfer of IgG in humans. This has relevance to the engineerwas cloned into the BglII site of the vector pAcUW51 (PharMingen, San Diego, CA) and the gene for β 2 -microglobulin ing of improved antibodies for therapy.
(28) into the BamHI site. Mouse and human FcRn were expressed and purified using the baculovirus system as Methods described previously (21) . The purity and mol. wt of proteins were checked by SDS-PAGE and HPLC.
Generation of plasmid for expression of mutated human IgG1
Treatment of human IgG1 with diethylpyrocarbonate (DEPC) DNA encoding the genomic region of the human IgG1 constant region (26) was a generous gift of Dr Jeff Foote (Fred Human myeloma IgG1 was kindly provided by Dr C. Medesan Hutchinson Cancer Center, Seattle, WA). This fragment was (Bucharest). The protein was purified by chromatography on subcloned as a BglII fragment into pGEM-T (Promega, MadiProtein G-Sepharose and Sephacryl S-200HR columns. IgG1 son, WI) and used as a template for splicing by overlap was dissolved in 0.1 M acetate buffer (pH 6.0) at 2 mg/ml extension (27) to generate the H435A mutant. The following and was treated with 10 µl DEPC (Sigma) (10 mg/ml in EtOH). mutagenic primers were used: H435Afor 5Ј-CTG CGT GTA The mixture was incubated at room temperature for 30 min GGC GTT GTG CAG-3Ј and H435Aback 5Ј-CTG CAC AAC and the reaction stopped by addition of a 5-fold molar excess GCC TAC ACG CAG-3Ј. PCR products were digested with of imidazole (0.2 mg/ml). The DEPC-treated human IgG1 was XmaI, and the resulting~400 bp XmaI fragment used to immediately gel filtered on Sephadex G-25M (Pharmacia) replace the wild-type segment of the C H 3 domain and downequilibrated in PBS (pH 7.5). The first peak was passed over stream sequences. Clones harboring the plasmid with the a Protein A-Sepharose column (Pharmacia) equilibrated in desired orientation of the gene fragment were identified and PBS, and the unbound fraction was collected, concentrated sequenced (Thermo Sequenase radiolabeled terminator cycle and kept sterile at 4°C for no longer than 2 weeks before use. sequencing kit; USB, Cleveland, OH) to verify that there were By using this concentration of DEPC, 90% of the IgG1 lost its no second site mutations. The entire human IgG1 constant Protein A-binding ability which could be restored by treatment region gene was then ligated as a BglII fragment into the with 1.0 M hydroxylamine (29). BamHI site of a modified form of αLys37 (26 were inserted into the intervillous space on the isolated equilibrium binding experiments, a flow rate of 10 µl/min was used. For kinetic analyses, higher flow rates of 80 µl/min were cotyledon close to the blanched area near the fetal intravillous tree. Briefly, the experimental conditions in the study were a used to minimize mass transport. The off-rate of the human FcRn:IgG1 interaction was immeasurably fast (assessed using temperature of 37°C, pH 7.4, maternal flow rate of EMEM containing 3% BSA at 17.0 ml/min and a fetal flow rate of 4.5 BIAevaluation 2.2.4; not shown) and for this reason, dissociation constants were estimated from equilibrium binding ml/min (34). Once the cotyledon was stabilized, 0.5 mM [ 14 C]antipyrine was added to the maternal circulation, and analyses. For these estimations, linear regression analysis in the MatLab programming language was used. However, the both the maternal and fetal circulations were open. The use of antipyrine, a freely diffusible small molecule, determines dissociation constant should be taken to be an apparent value as mouse/human FcRn has two possible interaction the maternofetal match in the isolated cotyledon. In a single pass of antipyrine, 45.3 Ϯ 10.7% (average of all experiments) sites on IgG which are not equivalent (31,32). In addition to using FcRn as analyte, HEL was also flowed over the chip in crossed the placental membranes. Values around 40% passage of antipyrine are indicative of a good maternal-fetal PBS (pH 7.2) plus 0.01% Tween 20 to ensure that the wildtype and H435A antibodies did not lose activity during match (34). Samples from both the maternal and fetal circulation were collected every 10 min for 1 h to determine the coupling.
transfer of antipyrine. Once the transfer was established, both Biotinylation of IgG maternal and fetal circulation were closed and IgG ligands were added to the maternal circulation (3 mg/150 ml medium), IgG (human IgG1, DEPC-human IgG1 or recombinant wildtype/H435A antibodies) were dissolved in 0.1 M carbonate/ allowed to mix for 5 min, and samples collected from the maternal and fetal circulation at 5 min, and 0.5, 1, 2 and 3 h. bicarbonate buffer (pH 8.6) at 2 mg/ml. Then 0.1 ml of EZLink Sulfo-NHS-biotin (Pierce, Rockford, IL) at 3 mg/ml in The samples were centrifuged, and the amount of IgG in both maternal and fetal compartments measured by ELISA (for distilled water was added and incubated at room temperature for 1 h. The mixture was gel filtered on Sephadex G-25M biotinylated IgG) or γ-counting after precipitation with 10% trichloracetic acid (for radioiodinated IgG). From those values, (Pharmacia, Uppsala, Sweden), and the first peak containing the biotinylated protein was collected, concentrated and the fetal/maternal ratio (%) was calculated for each time point (34). stored at 4°C for no longer than 1 month. Wild-type and H435A (IgG1) antibodies were radiolabeled with Na 125 I (Amersham, Arlington Heights, IL) using the sulfuric acid and the absorbance (490 nm) in each well determined.
Inhibition of IgG transfer was carried out by measuring the
Iodogen reagent as described previously (36) . Free iodine was removed by centrifugation on Microspin G-25 columns Placental transfer assays (Pharmacia, Piscataway, NJ). The specific radioactivities of the radiolabeled IgG were~10 7 c.p.m./µg, with Ͻ5% free Methods used in this study were modifications of those previously described (33, 34) . The use of the placental transfer iodine. The radiolabeled IgG were stored at 4°C for no more than 1 week before use. model is described in detail by Redman and colleagues (35) . Placentas were obtained from term vaginal or cesarean Pharmacokinetic analysis section deliveries. The use of human placentas in this study was approved by the University of Texas Southwestern MedPharmacokinetics of radiolabeled IgG were determined in Swiss mice (Harlan Sprague-Dawley Laboratory, Indianapolis, ical Center Institutional Review Board for Human Studies. Placentas were transported to the perfusion laboratory in a IN) as described previously (36) . bath of saline within minutes of separation from the uterus. A Isolation of human NK cells suitable non-traumatized cotyledon was identified, and the fetal artery and vein were cannulated with umbilical vessel Human NK cells were obtained from human blood by isolation of mononuclear cells on Ficoll-Hypaque (Sigma) followed by catheters. The catheterized cotyledon was gently perfused with perfusion media for 15-30 min to stabilize the tissue and removal of monocytes, T and B lymphocytes by negative selection using anti-CD14, -CD3 and -CD19 monoclonal remove retained blood. After 15 min the maternal side of the mouse antibodies (Caltag, Burlingame, CA), and capture with magnetic beads (Dynal, Oslo, Norway). Alternatively, cells were panned on tissue culture flasks (Becton Dickinson, Bedford, MA) to remove adherent cells and subsequently on anti-CD3-and -CD19-coated plates to remove T and B cells (37) . The purity of the NK population was verified by flow cytometric analysis using an anti-CD16 antibody (Caltag) and a FITC-goat anti-mouse antibody (Kirkegaard & Perry, Gaithersburg, MD). Human U937 (FcγRI ϩ ) and Daudi (FcγRII ϩ ) cells (2ϫ10 6 cells/ 0.5 ml RPMI 1640 medium with 5% FCS and 15 mM sodium azide) were treated with different concentrations of radiolabeled wild-type or H435A antibodies in either monomeric 
Binding of wild-type/H435A antibodies to FcγRIII bearing cells
Human NK (FcγRIII ϩ ) cells (2ϫ10 6 cells/0.5 ml RPMI 1640 medium with 5% FCS and 15 mM sodium azide) were treated with different concentrations of radiolabeled wild-type or H435A antibodies. After incubation at 4°C for 1 h, cells were washed twice with cold medium and the bound radioactivity determined for each concentration added.
Results

Interaction of recombinant antibodies with FcRn
The location of the H435A mutation on human IgG1 is shown differ by~50-fold (Ͻ130 nM and 6 µM) (31). Under the conditions of the SPR experiments, therefore, the higherin Fig. 1 . Recombinant human FcRn was expressed and purified from baculovirus-infected insect cells using Ni 2ϩ -affinity interaction would predominate and this is consistent with the linear Scatchard plots (Fig. 2B and D) . In addition, NTA-agarose followed by size exclusion chromatography. The interaction of the wild-type and H435A antibodies (human the experiments were carried out with immobilized antibodies and FcRn in solution to avoid avidity effects of immobilized IgG1-derived) with mouse and human FcRn was analyzed using SPR. H435A binds almost undetectably to human FcRn FcRn binding to both possible interaction sites on IgG1. However, when FcRn is membrane bound these avidity effects ( Fig. 2A) , whereas the wild-type IgG1 binds with an apparent dissociation constant (K D ) of 2.35 µM (Fig. 2B) . Similar results would be expected to enhance the FcRn:IgG1 interaction. Consistent with this, higher avidities are seen for FcRn:IgG were obtained when mouse FcRn was used as analyte, except that the mouse FcRn-IgG1 interaction is of significantly higher interactions when FcRn is immobilized on the sensor chip (21) (22) (23) . The SPR data clearly demonstrate that the H435A affinity (apparent K D ϭ0.265 µM) (Fig. 2C and D) . The stoichiometry of the mouse/human FcRn interaction with human mutation ablates binding of the recombinant IgG to human and mouse FcRn. Significantly, this mutation does not result IgG1 is 2FcRn:1IgG1 with two non-equivalent interaction sites (31,32) and in sedimentation equilibrium studies of the mouse in misfolding of the antibody as it retains binding to FcγRs (below) and the antigen, HEL (data not shown). FcRn:mouse IgG1 interaction the affinities of the two sites 
Ex vivo placental transfer
significantly reduces the transfer of IgG1 and this reduction is independent of the way in which the antibodies are labeled. The demonstration that H435A binds almost undetectably to Subsequently, the activities of the wild-type and H435A antihuman FcRn in SPR experiments indicated that it would be a bodies were directly compared in the placental transfer assay. useful tool to investigate the role of FcRn in the maternofetal The H435A mutation reduces the transfer of the recombinant transfer of IgG in an ex vivo human placental model. This antibody to levels similar to those observed for the DEPC in vitro model has been shown to be useful for the analysis treated IgG1 (Fig. 4) . The specificity of the transport was of the transfer of antibodies across the placenta by others demonstrated by measuring the transfer rate of [ 125 I]IgG1 in (39, 40) . In initial studies, in order to analyze the reliability of the absence and presence of an excess of unlabeled IgG in the placental transport model, IgG1 (from myeloma) and the maternal circulation. The transfer rate of [ 125 I]IgG1 was DEPC-treated IgG1 were used. DEPC treatment has been decreased from 0.41 to 0.04%/h by excess unlabeled IgG, shown previously to result in modification of histidines (29) representing an inhibition of 90.3% (Fig. 4C) . and, due to the role of histidines in FcRn:IgG binding (17, 22) , would be predicted to ablate this interaction. Consistent with Correlation between placental transfer and serum half-life this prediction, SPR experiments indicated that the DEPCin mice treated IgG1 did not bind detectably to FcRn (data not shown). Pilot experiments showed that due to the variability The effect of the H435A mutation on the serum pharmacokinetics of the H435A antibody in mice was analyzed. The in placentas, it was essential to compare the transfer of IgG1 and DEPC-IgG1 in the same experiment. These proteins were β-phase half-life of this mutated antibody is short (25.8 h) relative to that for the wild-type antibody (217.9 h) (Table 1 therefore either radioiodinated or biotinylated and the transfer quantitated by γ-counting (for radioiodinated IgG) or ELISA and Fig. 5 ). This indicates a direct correlation between the transfer of the mutated IgG across the human placenta (for biotinylated IgG). Figure 3 shows that DEPC treatment 
Interaction with FcγRIII
The Fc region is involved not only in binding to FcRn but also to FcγRIII, and this FcγR has been suggested to be involved in the placental transfer of IgG (41) . Although residues that are of importance for FcγRIII binding (25, 42) are distal to the FcRn interaction site (6, 17, 22, 24) , it was essential to exclude the possibility that the H435A mutation reduced IgG transfer by affecting binding to FcγRIII. The binding of (monomeric) wild-type or H435A antibodies to FcγRIII on human NK cells was therefore analyzed and there was no significant difference in the binding of the two antibodies (Fig. 6A ). Significant decreases in the amount of bound wild-type (95%) and H435A (78%) antibodies were observed in the presence of the antiFcγRIII antibody, 3G8 (Fig. 6B) . Similar levels of inhibition were observed in the presence of an excess of unlabeled human myeloma IgG1 (Fig. 6B) .
Interaction with FcγRI and II
FcγRI and II have been reported to be distributed in human placenta on Hofbauer and endothelial cells, and not in syncytiotrophoblasts, suggesting that they do not play a role in the transfer of maternal IgG (41) . However, to exclude the possibility that the effect of the H435A mutation on placental transfer was due to an alteration in binding to either or both of these Fc receptors, the binding of monomeric (to FcγRI ϩ U937 cells) or dimeric (to FcγRII ϩ Daudi cells) wild-type or In the current study we have used an ex vivo placental transfer assay to investigate a possible role for FcRn in mediating transfer of IgG across the human placenta. This observation that this FcR is expressed in placental syncytiotrophoblasts (7) (8) (9) (10) . In addition, the short serum half-life of has been carried out by comparing the transfer of a mutated human IgG1 molecule (H435A) with that of the wild-type, the H435A mutant in mice indicates that pharmacokinetic analyses can be used as an indicator of activity in human unmutated IgG1. The mutation results in loss of binding of the antibody to both human and mouse FcRn, whereas FcRn-mediated functions, and this is of obvious relevance for the engineering and pre-clinical analysis of antibodies of binding to FcγRI, FcγRII and FcγRIII is retained. The H435A mutant is transferred at background levels across the plapotentially therapeutic value.
In an earlier ex vivo placental study in which the transfer centa, indicating that binding to FcRn is a prerequisite for an antibody to cross the maternofetal barrier. This provides direct of all four human IgG isotypes were compared, the fetal/ maternal ratios for the four subclasses were reported to evidence to support a role for FcRn in the transcytosis of IgG across the human placenta and is consistent with the decrease in the order IgG4 Ͼ IgG1 Ͼ IgG3 Ͼ IgG2, with the transmission of human IgG3 being~65-69% of that of human phoblasts. In addition, in studies in which the transcytosis of human IgG1 and DEPC-treated IgG1 were analyzed using IgG1 (43) (46) . Consistent with this, the serum half-life of IgG1 is longer than that annexin II and PLAP, respectively, are unlikely to be involved (11) . Although a role for FcγRIII in IgG transport that of human IgG3 when determined in mice (45, 46) . In the current study, the H435A mutation ablates binding to both cannot be excluded, the observation that it does not bind to IgG2 or IgG4 (53,54) which are both transported (43) excludes human and mouse FcRn (Fig. 2) , whereas replacement of this residue by Arg in IgG3 has differential effects on the the possibility that it is the sole transporter. This is consistent with our data demonstrating that the H435A mutation, which interaction with FcRn from these two species (23, 46) (23) , there is some sequence that these Fc receptors are responsible for maternofetal IgG transport and the lack of effect of the H435A mutation on variation of FcRn residues that are involved in binding to IgG. These sequence differences may have particular impact on binding to these receptors supports their lack of involvement. Taken together with the current analyses, FcRn therefore the binding to IgG that vary at positions 435-436, as this region interacts in the vicinity of residue 137 (rodent) or appears to be the most likely candidate for the receptor that transports IgG across the placenta. the equivalent residue 135 (human) of FcRn which is not conserved across species (Leu135 in human and Glu/Asp137
In conclusion, our studies demonstrate that binding to FcRn is essential for the transplacental passage of an IgG. The in rodent) (23) . Thus, although mice are believed to be a good model for FcRn function in humans (46, 47) exceptions correlation between FcRn binding and placental transfer indicates that it may be possible to engineer antibodies that may exist, particularly for antibodies that vary in the region encompassing residues 435-436. This underscores the are maternofetally transferred with different efficiencies, in an analogous way to that used to increase the serum persistence importance of comparing binding of a (mutated) IgG to both rodent and human FcRn prior to drawing conclusions about of recombinant Fc fragments (16). Finally, the use of the ex vivo human placental assay provides a valuable humanactivity in FcRn-mediated functions across species.
Contractor and colleagues have observed that transport of based model for the preclinical evaluation of therapeutic antibodies and may be particularly useful as a predictor of IgG across the placenta is not an efficient process, with the majority of internalized IgG being broken down intracellularly serum persistence. (48) . Similarly, we observed that less than half of the radiolabel transferred across the placenta was precipitable with trichloroAcknowledgements acetic acid (data not shown). This suggests that the salvage the normal histological barrier together with the syncytiotro-
